Information Provided By:
Fly News Breaks for June 14, 2016
REGN
Jun 14, 2016 | 09:36 EDT
Chardan analyst Gbola Amusa said an Amgen (AMGN)brief dated June 6 provides none arguments related to irreparable harm and support a permanent injunction of Regeneron's (REGN) Praluent. The analyst said the arguments are consistent with his belief on Praluent could be removed from the US market in 2016 and cautions much of the market has yet to price the possibility that Praluent US economics may be neutralized by Amgen's patents. Amusa rates Regeneron a Sell with a $325 price target.
News For REGN From the Last 2 Days
There are no results for your query REGN